Clinical Trial Update: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A pharmacokinetic study evaluating the combination of lurbinectedin and irinotecan in selected solid tumors has completed (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Endometrial Cancer
• Epithelial Ovarian Cancer
• Gastroenteropancreatic Neuroendocrine Tumor
• Glioblastoma
• Mesothelioma
• Small Cell Lung Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• Irinotecan (Irinotecan)
• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: PharmaMar | Conditions: Advanced Solid Tumors, Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED